BridgeBio Pharma, Inc. (BBIO) has a consensus analyst rating of Buy, based on 26 analysts covering the stock. Of those, 25 recommend buying, 1 recommend holding, and 0 recommend selling.
The analyst consensus price target for BBIO is $99.85, representing a +28.1% upside from the current price of $77.93. Price targets range from a low of $83.00 to a high of $157.00.
